Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
94.20
-3.00 (-3.09%)
At close: Feb 21, 2025, 4:00 PM
93.67
-0.53 (-0.56%)
After-hours: Feb 21, 2025, 7:45 PM EST
Illumina Revenue
In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%. Illumina had revenue of $1.10B in the quarter ending December 29, 2024, a decrease of -1.60%.
Revenue (ttm)
$4.37B
Revenue Growth
-2.93%
P/S Ratio
3.43
Revenue / Employee
$421,601
Employees
10,370
Market Cap
14.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ILMN News
- 1 day ago - Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions - PRNewsWire
- 3 days ago - Illumina unveils first-of-its-kind spatial transcriptomics technology - PRNewsWire
- 3 days ago - Illumina To Webcast Upcoming Investor Session at the Advances in Genome Biology and Technology (AGBT) Conference - PRNewsWire
- 9 days ago - Trump's Cuts to Medical Research Are Hurting These Stocks - Barrons
- 12 days ago - Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability - Seeking Alpha
- 14 days ago - Illumina Analysts Slash Their Forecasts Following Q4 Results - Benzinga
- 15 days ago - Illumina, Inc. (ILMN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Illumina forecasts 2025 revenue largely below estimates - Reuters